These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 25751824)

  • 41. Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo.
    Lu J; Chong CR; Hu X; Liu JO
    J Med Chem; 2006 Sep; 49(19):5645-8. PubMed ID: 16970390
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiparasitic activities of novel, orally available fumagillin analogs.
    Arico-Muendel C; Centrella PA; Contonio BD; Morgan BA; O'Donovan G; Paradise CL; Skinner SR; Sluboski B; Svendsen JL; White KF; Debnath A; Gut J; Wilson N; McKerrow JH; DeRisi JL; Rosenthal PJ; Chiang PK
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5128-31. PubMed ID: 19648008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Fumagillin produced from an organism isolated in USSR].
    BEKKER ZE; SILAEV AB; MAKSIMOVA RA; SEMENOV MN; SMIRNOVA AD; MOSHKOVSKII ShD; NOSINA VD; VEIS RA; BEREZINA EK
    Antibiotiki (Mosc); 1957; 2(6):14-6. PubMed ID: 24544735
    [No Abstract]   [Full Text] [Related]  

  • 44. Culture condition-dependent metabolite profiling of Aspergillus fumigatus with antifungal activity.
    Kang D; Son GH; Park HM; Kim J; Choi JN; Kim HY; Lee S; Hong SB; Lee CH
    Fungal Biol; 2013 Mar; 117(3):211-9. PubMed ID: 23537878
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RK-95113, a new angiogenesis inhibitor produced by Aspergillus fumigatus.
    Asami Y; Kakeya H; Okada G; Toi M; Osada H
    J Antibiot (Tokyo); 2006 Nov; 59(11):724-8. PubMed ID: 17256472
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of genotoxic effects of fumagillin by cytogenetic tests in vivo.
    Stanimirovic Z; Stevanovic J; Bajic V; Radovic I
    Mutat Res; 2007 Mar; 628(1):1-10. PubMed ID: 17258933
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug.
    Pan D; Sanyal N; Schmieder AH; Senpan A; Kim B; Yang X; Hu G; Allen JS; Gross RW; Wickline SA; Lanza GM
    Nanomedicine (Lond); 2012 Oct; 7(10):1507-19. PubMed ID: 22709347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases.
    Cao Y
    Nat Rev Drug Discov; 2010 Feb; 9(2):107-15. PubMed ID: 20118961
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New and emerging drug molecules against obesity.
    George M; Rajaram M; Shanmugam E
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):65-76. PubMed ID: 24064009
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-nidatory effect of vaginally administered fumagillin in the rhesus monkey.
    Lalitkumar PG; Sengupta J; Dhawan L; Sharma DN; Lasley BL; Overstreet JW; Ghosh D
    Contraception; 2000 Sep; 62(3):155-9. PubMed ID: 11124364
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fumagillin, a Mycotoxin of
    Guruceaga X; Perez-Cuesta U; Abad-Diaz de Cerio A; Gonzalez O; Alonso RM; Hernando FL; Ramirez-Garcia A; Rementeria A
    Toxins (Basel); 2019 Dec; 12(1):. PubMed ID: 31861936
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stimulation of suicidal erythrocyte death by fumagillin.
    Zbidah M; Lupescu A; Jilani K; Lang F
    Basic Clin Pharmacol Toxicol; 2013 May; 112(5):346-51. PubMed ID: 23121865
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis.
    Winter PM; Neubauer AM; Caruthers SD; Harris TD; Robertson JD; Williams TA; Schmieder AH; Hu G; Allen JS; Lacy EK; Zhang H; Wickline SA; Lanza GM
    Arterioscler Thromb Vasc Biol; 2006 Sep; 26(9):2103-9. PubMed ID: 16825592
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does fumagillin control the recently detected invasive parasite Nosema ceranae in western honey bees (Apis mellifera)?
    Williams GR; Sampson MA; Shutler D; Rogers RE
    J Invertebr Pathol; 2008 Nov; 99(3):342-4. PubMed ID: 18550078
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of cells with the angiogenic inhibitor fumagillin results in increased stability of eukaryotic initiation factor 2-associated glycoprotein, p67, and reduced phosphorylation of extracellular signal-regulated kinases.
    Datta B; Majumdar A; Datta R; Balusu R
    Biochemistry; 2004 Nov; 43(46):14821-31. PubMed ID: 15544353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alphavbeta3-targeted nanotherapy suppresses inflammatory arthritis in mice.
    Zhou HF; Chan HW; Wickline SA; Lanza GM; Pham CT
    FASEB J; 2009 Sep; 23(9):2978-85. PubMed ID: 19376816
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases.
    Wang J; Lou P; Henkin J
    J Cell Biochem; 2000 Apr; 77(3):465-73. PubMed ID: 10760954
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fist report on fumagillin production by Aspergillus fumigatus sensu stricto gliotoxigenic strains recovered from raw cow milk and clinical samples in Argentina.
    Alonso VA; Velasco Manini MA; Pena GA; Cavaglieri LR
    Rev Argent Microbiol; 2022; 54(3):243-246. PubMed ID: 35654655
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [New antiparasitic drugs].
    Bouchaud O; Izri A
    Rev Med Interne; 2008 Jun; 29 Suppl 1():S15-7. PubMed ID: 18472191
    [No Abstract]   [Full Text] [Related]  

  • 60. Angiogenesis inhibitor attenuates parathyroid hormone-induced anabolic effect.
    Rhee Y; Park SY; Kim YM; Lee S; Lim SK
    Biomed Pharmacother; 2009 Jan; 63(1):63-8. PubMed ID: 18457934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.